Education
About Us
Working with TipRanks
Follow Us
Evelo Biosciences Inc (EVLO)
OTHER OTC:EVLO
Total Valuation
Evelo Biosciences has a market cap or net worth of $9.49K. The enterprise value is $143.54M.
Market Cap$9.49K
Enterprise Value$143.54M
Share Statistics
Evelo Biosciences has 18,982,838 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18,982,838
Owned by Insiders―
Owned by Institutions51.91%
Financial Efficiency
Evelo Biosciences’s return on equity (ROE) is 22.94 and return on invested capital (ROIC) is -201.37%.
Return on Equity (ROE)22.94
Return on Assets (ROA)-1.78
Return on Invested Capital (ROIC)-201.37%
Return on Capital Employed (ROCE)-2.08
Revenue Per Employee0.00
Profits Per Employee-1.74M
Employee Count66
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Evelo Biosciences is -1.23. Evelo Biosciences’s PEG ratio is 0.03.
PE Ratio-1.23
PS Ratio0.00
PB Ratio-28.11
Price to Fair Value-28.11
Price to FCF-1.38
Price to Operating Cash Flow-1.39
PEG Ratio0.03
Income Statement
In the last 12 months, Evelo Biosciences had revenue of 0.00 and earned -114.53M in profits. Earnings per share was -26.28.
Revenue0.00
Gross Profit0.00
Operating Income-108.47M
Pretax Income-113.60M
Net Income-114.53M
EBITDA-106.34M
Earnings Per Share (EPS)-26.28
Cash Flow
In the last 12 months, operating cash flow was -73.70M and capital expenditures -287.00K, giving a free cash flow of -73.99M billion.
Operating Cash Flow-73.70M
Free Cash Flow-73.99M
Free Cash Flow per Share-3.90
Dividends & Yields
Evelo Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta25.68
52-Week Price Change-66.67%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)13.00
Important Dates
Evelo Biosciences upcoming earnings date is Aug 1, 2024, TBA Not Confirmed.
Last Earnings DateMay 30, 2024
Next Earnings DateAug 1, 2024
Ex-Dividend Date―
Financial Position
Evelo Biosciences as a current ratio of 4.16, with Debt / Equity ratio of -1024.40%
Current Ratio4.16
Quick Ratio4.16
Debt to Market Cap0.31
Net Debt to EBITDA-0.03
Interest Coverage Ratio-23.22
Taxes
In the past 12 months, Evelo Biosciences has paid 930.00K in taxes.
Income Tax930.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Evelo Biosciences EV to EBITDA ratio is -1.35, with an EV/FCF ratio of -1.41.
EV to Sales0.00
EV to EBITDA-1.35
EV to Free Cash Flow-1.41
EV to Operating Cash Flow-1.42
Balance Sheet
Evelo Biosciences has $17.26M in cash and marketable securities with $33.95M in debt, giving a net cash position of $16.69M billion.
Cash & Marketable Securities$17.26M
Total Debt$33.95M
Net Cash$16.69M
Net Cash Per Share$0.88
Tangible Book Value Per Share-$1.15
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Evelo Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―